Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
Rhea-AI Summary
Syndax (Nasdaq: SNDX) will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET the same day.
Investors can join via the live webcast or dial in using the provided conference numbers and Conference ID. A replay will be posted on the Investors section of the company website approximately 24 hours after the call and will remain available for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – SNDX
On the day this news was published, SNDX gained 1.88%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: ARDX up 1.93%, NTLA down 1.92%, while SNDX slipped -0.44%, suggesting stock-specific trading rather than a clear sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Conference participation | Neutral | -1.4% | Announcement of CEO fireside chat at Guggenheim biotech summit. |
| Feb 04 | Equity inducement grants | Neutral | -3.9% | Inducement option grants to new employees under 2023 plan. |
| Jan 12 | Preliminary 2025 results | Positive | -1.3% | Preliminary 4Q25 and 2025 revenues plus cash and trial plans. |
| Jan 07 | Access program launch | Positive | +8.7% | Managed Access Program expanding Revuforj reach outside U.S. |
| Jan 05 | Conference presentation | Neutral | -5.1% | Planned CEO presentation at J.P. Morgan Healthcare Conference. |
Recent neutral corporate updates often coincided with modest share declines, while the Revuforj access expansion saw a stronger positive reaction.
Over the past months, Syndax issued several corporate and clinical-access updates. On Jan 5, 2026, it announced a J.P. Morgan conference presentation, followed by preliminary 2025 financial highlights on Jan 12, 2026. A multi‑regional Revuforj access program on Jan 7, 2026 drew the strongest reaction at +8.7%. More recently, equity inducement grants and a Guggenheim summit appearance saw modest declines. Today’s earnings-date announcement fits this cadence of scheduled corporate communications.
Market Pulse Summary
This announcement schedules Syndax’s detailed fourth quarter and full year 2025 results for February 26, 2026, with a call at 4:30 p.m. ET. It follows January’s preliminary 2025 financial update and a Revuforj access expansion that previously drew a strong reaction of +8.7%. Investors may focus on how final figures compare with those preliminary numbers and on updated guidance and pipeline timelines discussed during the webcast.
AI-generated analysis. Not financial advice.
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, February 26, 2026.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax4Q25
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://sndx-4q25.open-exchange.net/
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
When will Syndax (SNDX) release its Q4 and full year 2025 results and host the earnings call?
How can investors access the Syndax (SNDX) February 26, 2026 webcast and slides?
What are the dial-in details for the Syndax (SNDX) conference call on February 26, 2026?
Will Syndax (SNDX) provide a replay of the February 26, 2026 earnings call and for how long?
Where on the Syndax (SNDX) website will the February 26, 2026 webcast replay be posted?
Is there a direct webcast URL provided for the Syndax (SNDX) February 26, 2026 earnings presentation?
